What it is
Semax is a short, man-made chain of seven amino acids (a peptide). It was developed in Russia in 1982 at the Institute of Molecular Genetics to help people recover from strokes and brain injuries. It has been a prescription medicine in Russia for over three decades and was added to the Russian List of Vital and Essential Drugs in 2011. Doctors there prescribe it for stroke recovery, brain injury, cognitive decline, and optic nerve disease. It is not approved by the FDA and is sold as a research chemical.
It is built from a small piece of a natural body hormone called ACTH — adrenocorticotropic hormone. ACTH normally tells the adrenal glands to release cortisol. Semax uses only amino acids 4 through 10 of that hormone, so it has no effect on cortisol. A short extra tail called Pro-Gly-Pro was added to make it more stable and help it reach the brain.
Semax is not a stimulant like caffeine. It raises a protein called BDNF (brain-derived neurotrophic factor), which the brain uses to grow new nerve cells, form memories, and cope with stress. Think of BDNF as fertiliser for the brain.
It arrives as a dry powder in a 10 mg glass vial. You add bacteriostatic water to turn it into a liquid, then inject it just under the skin — a subcutaneous injection. A nasal spray version is covered on a separate page. It cannot be taken by mouth because stomach acid breaks it down.
Semax is a synthetic heptapeptide analogue of the ACTH (4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro), developed in 1982 at the Institute of Molecular Genetics in Russia for stroke and traumatic brain injury recovery. It has been prescribed in Russia for over three decades for stroke, TBI, cognitive decline, and optic nerve disease, was added to the Russian List of Vital and Essential Drugs in 2011, is not FDA approved, and is not on the FDA Category 2 restricted list as of early 2026.
The C-terminal Pro-Gly-Pro extension confers peptidase resistance and improved central penetration, and the truncation removes corticotropic activity, so the compound is neuroactive without engaging the hypothalamic–pituitary–adrenal axis or altering cortisol.
Its principal mechanism is upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, alongside nerve growth factor expression, supporting neuronal survival, synaptogenesis, and plasticity. It also modulates dopaminergic and serotonergic transmission and inhibits enkephalin-degrading enzymes, prolonging endogenous regulatory peptide signalling.
Onset is rapid: effects appear within about 20 minutes, peak around 90 minutes, and persist 20 to 24 hours. It is supplied as lyophilised powder in a 10 mg vial for reconstitution with bacteriostatic water and subcutaneous injection; the intranasal formulation is covered separately. Oral administration is not viable owing to gastric degradation.
How it works
Semax works through several linked routes in the brain.
Growth factors. Its main action is raising BDNF, a protein that keeps existing nerve cells alive, helps new ones grow, and strengthens the connections used for learning and memory. This is the same protein exercise raises. In rat studies a single dose raised BDNF protein about 1.4-fold, raised BDNF gene activity about three-fold, and increased activation of the BDNF receptor (TrkB) 1.6-fold. Effects begin within about 20 minutes, peak around 90 minutes, and last 20 to 24 hours. It also raises nerve growth factor (NGF), another protein that supports nerve cells.
Brain chemicals. Semax does not spike dopamine on its own. Instead it makes other things that release dopamine work better. A 1995 study showed dopamine release was much higher when Semax was given 20 minutes before amphetamine than with amphetamine alone. This is why people report that caffeine feels stronger while using Semax. It also speeds up serotonin turnover, which may explain the mood benefits.
Protection. It lowers inflammation in the brain, protects nerve cells from oxidative damage, and in rats increased growth of blood vessel cells, support cells, and progenitor cells that help repair the brain.
Genes. Semax influences over 1,500 genes tied to brain function, immunity, and blood vessels, turning up protective genes and turning down inflammatory ones.
Brain networks. Brain scans show it boosts activity in the default mode network — the part of the brain used for creativity, visualisation, and problem solving — within minutes.
BDNF/TrkB upregulation is the primary mechanism. In the rat hippocampus a single intranasal dose increased BDNF protein approximately 1.4-fold, BDNF gene expression approximately three-fold, and TrkB receptor activation 1.6-fold (Dolotov et al., Brain Research, 2006). Onset is within about 20 minutes, peak around 90 minutes, duration 20 to 24 hours. This trophic drive underpins the original stroke indication, where rewiring and functional rerouting depend on BDNF availability.
Monoaminergic modulation. Semax does not directly elevate dopamine; it potentiates evoked release. A 1995 Institute of Molecular Genetics study showed that Semax given 20 minutes before amphetamine produced markedly greater dopamine release than amphetamine alone, and Eremin et al. (Neurochemical Research, 2005) confirmed activation of dopaminergic and serotoninergic systems in rodents, including increased serotonin turnover. This accounts for reports of enhanced caffeine response and of interest without jitteriness, and for the anxiolytic and mood signal.
Neuroprotection. Reduction of pro-inflammatory cytokines, antioxidant activity against oxidative stress, and NGF upregulation. In rat ischaemia models Semax increased proliferation of endothelial, neuroglial, and progenitor cells (Stavchansky et al., 2011).
Transcriptional effects. A genome-wide analysis (Medvedeva et al., BMC Genomics, 2014) in rat focal ischaemia found over 1,500 genes modulated, with immune and vascular genes enhanced and inflammatory genes suppressed; immune modulation and vascular support were identified as key neuroprotective mechanisms.
Enkephalinase inhibition prolongs endogenous regulatory peptide signalling, consistent with the analgesic signal.
Network effects. Resting-state fMRI shows increased default mode network activity and connectivity within minutes of administration, associated with problem solving, memory, and creative cognition.
What it does
The effect people look for first is sharper focus and memory. In a study of healthy men working while tired, a single 1 mg dose gave 71% accuracy on a memory test against 41% for the control group, and the effect lasted up to 24 hours. Earlier testing showed 31% more correct answers than the group not using Semax.
It protects nerve cells. This is where the strongest evidence sits: in Russia it is used for acute stroke and head injury, where it reduces brain damage and speeds recovery. Research also covers the optic nerve, ADHD symptoms, opioid or alcohol withdrawal, nerve damage from diabetes, and pain relief.
In animal studies it lowers anxiety, lifts mood, and blunts the body's response to long-term stress. Users report feeling calmer and more motivated, and that caffeine works better. Be aware that a 1996 study found it can increase anxiety in some people at higher doses, so the dose matters.
The feel is subtle. Users describe a clean, clear-headed boost rather than a stimulant rush. A healthy brain gets a refinement; a stressed, injured, or inflamed brain often sees more.
Cognition: BDNF/NGF-driven synaptic plasticity in hippocampus and cortex. A 2007 study of healthy men under fatigue found 71% memory-test accuracy after a single 1 mg dose versus 41% in controls, lasting up to 24 hours; a separate result documents 31% more correct responses than control. Users report improved focus, verbal fluency, faster learning, and enhanced default mode network-linked creativity.
Neuroprotection: the strongest clinical evidence. Gusev et al. (2018) in 110 ischaemic stroke patients showed sustained plasma BDNF elevation and improved motor performance and Barthel index scores; a 2001 study of 30 acute-phase patients showed accelerated return of neurological function. Russian clinical data report 70 to 80% therapeutic efficacy in vascular, inflammatory, and toxic optic nerve conditions. Also studied in ADHD, opioid and alcohol withdrawal, non-proliferative diabetic neuropathy, and analgesia via enkephalinase inhibition.
Neuropsychiatric: anxiolytic and antidepressant activity in animal models through serotonergic and BDNF mechanisms, with normalisation of the chronic stress response, including prevention of stress-induced liver enzyme elevation. A 1996 study identified an anxiogenic component at certain doses, so the dose–response is biphasic in susceptible individuals. Dopamine potentiation rather than release produces an optimisation-like rather than stimulant-like subjective profile.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Sharper focus and attention, especially during hard mental work or when tired — 71% test accuracy versus 41% for controls after a single 1 mg dose.Limited human data
- Better memory — in testing, 31% more correct answers than the control group.Limited human data
- Faster learning and better recall, reported by users.Anecdotal
- Protects nerve cells from damage caused by stroke, injury, or diseases that break down brain tissue; used in Russia for stroke and head injury.Limited human data
- Lowers anxiety and lifts low mood in animal studies.Animal or lab only
- Helps the body cope with long-term stress.Animal or lab only
- Helps nerve cells survive, and encourages new connections between them.Animal or lab only
- Helps nerve cells adapt after an injury or a change in environment.Animal or lab only
- Protects the optic nerve, with 70 to 80% efficacy reported in Russian trials for vascular, inflammatory, and toxic optic nerve conditions.Limited human data
- Improves the brain's nourishment and the connections across its networks.Animal or lab only
- May help with ADHD symptoms.Animal or lab only
- Blocks the enzymes that break down the body's own natural signalling and pain-relieving peptides, so those last longer.Animal or lab only
- May support recovery from opioid or alcohol withdrawal.Animal or lab only
- Improves early-stage nerve damage caused by diabetes.Limited human data
- May relieve pain.Animal or lab only
- Makes caffeine and similar things feel more effective, without being a stimulant itself.Anecdotal
- Focus and attention under cognitive load or fatigue: 71% memory-test accuracy versus 41% for controls after a single 1 mg dose, lasting up to 24 hours.Limited human data
- Memory enhancement: 31% more correct responses than control on memory testing.Limited human data
- Neuroprotection against ischaemic, traumatic, and neurodegenerative injury; clinical use in acute stroke and TBI with improved Barthel index outcomes.Limited human data
- Antidepressant and anxiolytic activity in animal models via serotonergic and BDNF mechanisms.Animal or lab only
- Stress resilience: normalises the chronic stress response, preventing stress-induced liver enzyme elevation and behavioural change in animals.Animal or lab only
- Supports neuronal survival and promotes synaptogenesis and neuroplasticity via BDNF/NGF upregulation.Animal or lab only
- Improves neuronal adaptation to injury and environmental change.Animal or lab only
- Protects the optic nerve; 70 to 80% therapeutic efficacy in Russian clinical data with improved visual acuity, visual field, and colour vision.Limited human data
- Improves trophic supply to the brain and supports network connectivity, including default mode network activity.Animal or lab only
- Reported benefit in ADHD symptom management.Animal or lab only
- Inhibits enkephalin-degrading enzymes and the enzymes that clear regulatory peptides, prolonging endogenous peptide signalling.Animal or lab only
- Studied as support during opioid or alcohol withdrawal.Animal or lab only
- Documented improvement in non-proliferative diabetic neuropathy.Limited human data
- Analgesic potential, consistent with the enkephalinase inhibition.Animal or lab only
- Potentiates evoked dopamine release, enhancing the response to caffeine and other stimulants without direct stimulant action.Anecdotal
What to expect
Semax is fast for a peptide. Effects usually start within 20 minutes, peak around 90 minutes, and last 20 to 24 hours from each dose.
In the first few days most people notice small gains in focus, finding words, and mental clarity. Some say their brain feels sharper. Some feel more interested in things without feeling wired. Others notice caffeine works better. Some people feel nothing at first and then notice effects around days 5 to 7.
Over the first 1 to 2 weeks of steady use the benefits deepen: memory, learning, and problem solving improve more clearly.
Do not expect a switch flipping on like a stimulant. If you are healthy and your brain already works well, you will get a refinement, not a revolution. If your brain is under stress, recovering from injury, or inflamed, the effects are often stronger. It will not fix brain fog caused by 5 hours of sleep and poor food; fix the basics first.
The human evidence comes from Russian studies with small numbers of people, so treat timelines as guides, not promises.
Pharmacodynamic onset is rapid relative to most peptides: within about 20 minutes, peak around 90 minutes, and a 20 to 24 hour duration per dose. Human timeline data derive from Russian clinical studies and user reports rather than Western controlled trials.
Days 1 to 3: subtle gains in focus, verbal fluency, and clarity are commonly reported, with enhanced interest and motivation in the absence of stimulant-type arousal, and a noticeably stronger caffeine response consistent with dopamine potentiation. A subset report no effect until days 5 to 7.
Weeks 1 to 2: consolidation of memory, learning, and problem-solving benefits as BDNF-mediated plasticity accumulates.
Effect magnitude is context-dependent. In healthy, well-functioning individuals the change is a refinement; under stress, post-injury, or in an inflamed state the response is typically more pronounced, consistent with the trophic and anti-inflammatory mechanism. Sleep deprivation and poor nutrition are not offset by the compound.
All human studies are Russian with sample sizes below FDA-approval norms, and long-term safety is not established by Western standards, although over 30 years of clinical use report no hormonal disruption, dependency, or withdrawal.
Reconstitution and dosing
Semax comes as a dry powder in a 10 mg vial. Before the first dose you mix it with bacteriostatic water — this is called reconstitution. Add the water slowly down the inside wall of the vial, then swirl gently. Do not shake. The site's standard mix is 3 mL (300 units on an insulin syringe). Bacteriostatic water is for injection only; saline is used for the nasal version, which has its own page.
Inject under the skin (subcutaneous) once a day in the morning. Do not dose late in the day, because it can disturb sleep. Food does not matter; no fasting is needed.
The standard injectable protocol is 200 to 600 mcg per day. Start at the low end. By goal, in practice: 200 to 400 mcg daily for general cognitive support, 400 to 600 mcg daily for neuroprotection, and 600 mcg daily for recovery after an injury (clinical studies used up to 6,000 mcg). If you have a history of anxiety, start at the lowest dose and watch how you respond.
Cycle it: 10 to 14 days on, then 2 to 4 weeks off, repeated as needed. Semax works on BDNF pathways, and running it non-stop makes them adapt so the benefit fades. Longer 6 to 8 week cycles building from 167–250 mcg up to 500 mcg, followed by a 6 to 8 week break, are also used.
No published study has set the ideal daily dose for everyday cognitive use; these protocols come from practice, not trials.
Vial is 10 mg lyophilised powder. Reconstitute with bacteriostatic water added down the vial wall and swirled, not shaken; 3 mL (300 units) gives 3.33 mg/mL. Bacteriostatic water is for the injectable route only; the nasal formulation uses 1 mL sterile saline and is covered separately.
Route is subcutaneous, once daily, morning. Late dosing is the usual cause of insomnia given dopaminergic activation and increased cortical activity. Fasting is not required; there is no food interaction, and GH secretagogues run alongside keep their own fasted schedule.
Standard practical protocol: 200 to 600 mcg per day, 10 to 14 days on, 2 to 4 weeks off, repeated as needed. Application tiers in practice: cognitive support 200 to 400 mcg daily; neuroprotection 400 to 600 mcg daily; post-injury recovery 600 mcg daily, with clinical stroke work using up to 6,000 mcg per day. Individuals with anxiety history should start at the lowest dose given the anxiogenic component reported at higher doses.
Cycling is mechanistically necessary: continuous BDNF pathway stimulation leads to adaptation and diminishing returns. Longer schedules are also used in practice — 6 to 8 weeks on with a 6 to 8 week washout, titrating from 167–250 mcg in weeks 1–2 through 250 mcg to 500 mcg; and a short high-dose course of 6 mg once daily for 10 days drawn from stroke and TBI work, reconstituted at 1 mL (10 mg/mL) to keep injection volume practical.
Studied doses for reference: Gusev (2018) used 6,000 mcg per day intranasally for 10 days, a 20 day break, then a second 10 day course; the 2007 cognitive study used a single 1 mg (1,000 mcg) intranasal dose; preclinical rat work used 50 to 600 mcg/kg intranasally. No published dose-finding studies exist for daily cognitive protocols. N-Acetyl Semax Amidate is reported as more potent, so lower doses apply to that variant.
Standard, 10 mg vial
Mix with 3 mL (300 units) of bacteriostatic water.
3.33 mg/mL · 33.33 mcg per unit
Cycle: 10–14 days on, then 2–4 weeks off; repeat as needed · Frequency: 1×/day, morning, subcutaneous
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 200 mcg | 6 units | 1×/day |
| Full | 600 mcg | 18 units | 1×/day |
Alternative protocols
Alternative protocols reflect older community practice and are kept for reference.
Alternative, 10 mg vial — standard protocol
Mix with 3 mL (300 units) of bacteriostatic water.
3.33 mg/mL · 33.33 mcg per unit
Cycle: 6–8 weeks, then 6–8 week washout · Frequency: 1×/day in the morning, 5–7 days per week
| When | Dose | Draw | How often |
|---|---|---|---|
| Weeks 1–2 (167–250 mcg, ramp-in) | 167 mcg | 5.01 units | 1×/day |
| Weeks 3–4 | 250 mcg | 7.5 units | 1×/day |
| Weeks 5–8 | 500 mcg | 15 units | 1×/day |
Alternative, 10 mg vial — daily 8-week protocol
Mix with 3 mL (300 units) of bacteriostatic water.
3.33 mg/mL · 33.33 mcg per unit
Cycle: 8 weeks, then 4–8 week washout · Frequency: 1×/day, daily (7 days a week)
| When | Dose | Draw | How often |
|---|---|---|---|
| Weeks 1–4 | 250 mcg | 7.5 units | 1×/day |
| Weeks 5–8 | 500 mcg | 15 units | 1×/day |
Alternative, 10 mg vial — maximum protocol (stroke or traumatic brain injury recovery)
Mix with 1 mL (100 units) of bacteriostatic water.
10 mg/mL · 100 mcg per unit
Cycle: 10 days · Frequency: 1×/day for 10 days
| When | Dose | Draw | How often |
|---|---|---|---|
| Days 1–10 (6 mg) | 6 mg | 60 units | 1×/day |
10 mg in 3 mL is 3.33 mg/mL, or 33.33 mcg per unit. Draw 6 units (0.06 mL) for 200 mcg.
Who should avoid it
- Anyone pregnant or breastfeeding.
- Anyone under 18. Safety in children has not been established.
- Anyone taking an MAO inhibitor (a type of antidepressant). Do not combine the two.
- Anyone with high blood pressure that is not under control. Semax can raise blood pressure at higher doses.
- Anyone who reacts badly to Semax itself — a rash, swelling, or itching after a dose is a sign of an allergic reaction, and you should stop.
- Anyone whose hormone system is unstable.
- Anyone with a serious mental health condition — especially active psychosis (losing touch with reality), a manic episode (a period of extreme, driven high mood), a severe anxiety disorder, or anxiety that is not under control. Semax stimulates the brain and could make these worse.
- Use caution if you have a history of anxiety disorder or panic disorder. Start at the lowest dose and watch how you feel, because some people get more anxious at higher doses.
- Use caution if you have bipolar disorder, including periods of mania or hypomania.
- Use caution if you have a psychotic disorder or schizophrenia.
- Use caution if you have diabetes. Semax may push blood sugar up.
- Use caution if you take other stimulants or brain-boosting supplements. Semax makes them hit harder, which can tip into feeling overstimulated.
- Use caution if you also use a nasal decongestant spray and take Semax by nose on other days.
- Use caution if male pattern hair loss runs in your family. Some users report shedding, though this is not proven.
- Pregnancy and lactation: contraindicated.
- Under 18: safety profile not established; paediatric use should be avoided.
- MAO inhibitors: contraindicated. Semax potentiates dopamine release and increases serotonin turnover, so combination with MAOI therapy is not acceptable.
- Uncontrolled hypertension: contraindicated. Blood pressure increase is reported at higher doses.
- Known hypersensitivity to Semax: discontinue; hypersensitivity indicates an allergic reaction.
- Endocrine instability: avoid.
- Severe psychiatric disorder — active psychosis, manic episodes, severe anxiety disorders, or uncontrolled anxiety: the stimulatory and neuroactive profile may worsen the psychiatric state. A 1996 study noted an anxiogenic component at certain doses.
- History of anxiety disorder: use with caution given dopaminergic, serotonergic, and BDNF-mediated CNS modulation; start at the lowest effective dose and monitor.
- History of panic disorder: use with caution.
- Bipolar disorder including hypomania or mania: use with caution.
- Psychotic disorders or schizophrenia: use with caution. Discontinue if clinically significant psychiatric symptoms emerge or worsen.
- Diabetes: use with caution; blood glucose elevation is reported in diabetics.
- Concurrent stimulants or other nootropics: use with caution; dopamine potentiation amplifies their effect and can produce overstimulation.
- Other nasal vasoconstrictors: caution if the intranasal route is also used.
- Predisposition to androgenetic alopecia: theoretical BDNF–hair follicle cycling concern; not established in clinical data.
Side effects
- Headache — often from dehydration or from a dose that is too high.
- Nausea.
- Trouble sleeping, especially if taken late in the day.
- Anxiety, more likely at higher doses and in people already prone to it.
- Mild dizziness or light-headedness.
- Slight restlessness if the dose is too high.
- Short-lived mood changes or irritability.
- A rise in blood sugar, mainly in people with diabetes; very rare otherwise.
- A rise in blood pressure at higher doses.
- A reaction where you inject — redness, swelling, or itching.
- Nose irritation, dryness, or temporary discolouration inside the nose if you also use the nasal form.
- Some users report temporary hair shedding. This is not proven in studies.
- Agitation or restlessness are possible. Stop if any mental health symptom appears or gets worse.
- Headache; users attribute most cases to dehydration or excessive dose.
- Nausea.
- Insomnia or light sleep — the reason protocols specify morning dosing.
- Anxiety, particularly at higher doses and in anxiety-prone individuals; an anxiogenic component at certain doses is documented (1996).
- Mild dizziness or light-headedness.
- Slight restlessness at excessive doses.
- Temporary mood changes or irritability.
- Blood glucose elevation in diabetics; very rare slight increase otherwise.
- Blood pressure increase at higher doses.
- Injection site reaction: redness, swelling, and/or itching.
- Nasal irritation, dryness, or usually temporary discolouration of the nasal cavity where the intranasal route is also used.
- Reports of temporary hair shedding; not established in clinical data and mechanistically speculative.
- Neuropsychiatric: agitation, irritability, restlessness, or insomnia. Discontinue if clinically significant psychiatric symptoms emerge or worsen.
- Published research: multiple Russian clinical studies report no significant adverse effects, no hormonal disruption, and no dependency or withdrawal. The 110-patient stroke study at 6,000 mcg per day reported no major adverse events.
What the evidence shows
All the human research on Semax comes from Russia, where it has been a prescription medicine since the early 1990s. There are no published Western clinical trials as of early 2026.
The strongest evidence is for stroke recovery. In a 2018 study by Gusev and colleagues, 110 people recovering from a stroke were given 6,000 mcg a day by nose for 10 days, had a 20 day break, then did another 10 day course. Blood levels of BDNF (a protein that helps brain cells grow and connect) went up and stayed up. Movement improved on standard tests, and the patients became more independent in daily tasks. A 2001 study of 30 people in the early phase of a stroke found Semax sped up the return of movement.
For thinking and memory, a 2007 study gave healthy men a single 1 mg dose by nose while they did tasks when tired. They scored 71% on a memory test against 41% for the group without Semax, and the effect lasted up to 24 hours.
Russian eye clinics report 70 to 80% success in optic nerve conditions caused by poor blood supply, inflammation, or toxins, with better sharpness, field of vision, and colour vision.
Animal studies explain how it works. Dolotov and colleagues (Brain Research, 2006) found a 1.4 fold rise in BDNF and a 1.6 fold rise in its receptor in the rat brain, with better learning. Medvedeva and colleagues (BMC Genomics, 2014) found it changed over 1,500 genes, boosting repair genes and calming inflammation genes. Eremin and colleagues (Neurochemical Research, 2005) showed it boosts the effect of other dopamine-releasing substances rather than releasing dopamine itself.
Keep in mind the studies are small by Western standards, and there are no published dose-finding studies for the everyday cognitive doses people use.
The entire human evidence base is Russian. No Western clinical trials have been published as of early 2026, and sample sizes are small relative to FDA-standard programmes.
Stroke: Gusev and colleagues (2018) enrolled 110 ischaemic stroke patients on 6,000 mcg per day intranasally for 10 days, a 20 day break, then a second 10 day course. Plasma BDNF rose and remained elevated throughout; motor performance improved on standardised testing and functional independence improved on the Barthel index. A 2001 study of 30 acute-phase patients showed accelerated return of neurological — particularly motor — function.
Cognition: a 2007 study in healthy men performing tasks under fatigue found 71% memory-test accuracy after a single 1 mg intranasal dose versus 41% in controls, with effect persisting up to 24 hours.
Optic nerve: Russian clinical data report 70 to 80% therapeutic efficacy in vascular, inflammatory, and toxic optic neuropathies, with gains in acuity, visual field, and colour vision.
Mechanism: Dolotov and colleagues (Brain Research, 2006) showed intranasal Semax produced a 1.4 fold increase in hippocampal BDNF protein, approximately three fold BDNF gene expression, and a 1.6 fold increase in TrkB activation, with improved learning and memory performance; onset around 20 minutes, peak around 90 minutes, duration 20 to 24 hours. Medvedeva and colleagues (BMC Genomics, 2014) reported modulation of over 1,500 genes in rat focal ischaemia, upregulating immune and vascular genes and suppressing inflammatory genes. Eremin and colleagues (Neurochemical Research, 2005) demonstrated activation of dopaminergic and serotonergic systems; a 1995 Institute of Molecular Genetics study showed Semax given 20 minutes before amphetamine markedly potentiated dopamine release relative to amphetamine alone. Resting-state fMRI shows increased default mode network activity and connectivity within minutes. Stavchansky (2011) and Glazova (2009) describe proliferative and neurotrophin-transcription effects after experimental ischaemia.
Safety: clinical use since the early 1990s with no significant adverse effects, hormonal disruption, or dependency reported. No published dose-finding studies support the daily cognitive protocols, and long-term safety is not established to Western standards.
User reports
From public forums
Most users describe a clean lift in focus, clearer thinking, and easier speech, without the jittery feeling of a stimulant. A very common report is that coffee works noticeably better while on Semax. Some notice more creative thinking and sharper visual processing.
In the first few days, changes are subtle. Some people feel nothing until around days 5 to 7. Over 1 to 2 weeks, memory, learning, and problem solving tend to improve further. If you are healthy and already thinking well, expect a refinement rather than a transformation. If your brain is under stress, inflamed, or recovering from injury, the effects are usually more obvious. It does not replace sleep and a decent diet.
Mood reports are mixed. Many feel calmer and more motivated, but some feel more anxious at higher doses, especially with the stronger N-Acetyl Semax Amidate version. If you already have anxiety, start low and watch carefully.
Most users prefer the nasal spray for speed and convenience; those who want exact doses inject under the skin. Side effects are usually minor: mild headache, poor sleep if dosed late, and nose irritation with the spray. A few users report temporary hair shedding, which studies have not confirmed.
Users consistently report improved focus, verbal fluency, and mental clarity described as a clean cognitive boost without stimulant jitteriness. Potentiation of caffeine and other stimulants is one of the most frequently repeated observations and is consistent with the dopamine-potentiating rather than dopamine-releasing profile. Enhanced creative and visual processing is also reported.
Onset is fast for a peptide — around 20 minutes to first effect, peak around 90 minutes, 20 to 24 hours per dose — but cumulative benefit builds over 1 to 2 weeks of consistent use, and some users note nothing until days 5 to 7. The effect size is modest in healthy, well-rested individuals and more pronounced under stress, neuroinflammation, or post-injury.
Anxiety reports are bidirectional: many users describe calm and motivation, while a minority report increased anxiety at higher doses, particularly with N-Acetyl Semax Amidate, which users regard as more potent and therefore requiring lower doses. No separate clinical data exist for that variant.
Intranasal administration is preferred for convenience and onset; subcutaneous injection is chosen for dosing precision. Users mixing nasal preparations use sterile saline rather than bacteriostatic water.
Adverse reports are mostly mild: nasal irritation and dryness, dose- or dehydration-related headache, and insomnia from late dosing. Temporary hair shedding is reported by some users but is not established in clinical literature.
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
The most common pairing. Selank is calming where Semax is activating, so together they suit anxiety, focus, and recovery from brain inflammation better than either on its own. In practice Semax is used at 200 to 400 mcg in the morning and Selank at 200 to 400 mcg in the morning and/or afternoon.
The canonical Russian regulatory-peptide pairing. Selank's tuftsin-derived GABAergic anxiolysis offsets the stimulatory edge of Semax's monoaminergic activation and dopamine potentiation, while both converge on BDNF-mediated neuroplasticity. Typical practice: Semax 200 to 400 mcg morning, Selank 200 to 400 mcg morning and/or afternoon, co-administered intranasally or subcutaneously.
Added when there is physical injury as well as brain recovery to think about. BPC-157 repairs tissue and calms inflammation, and there are no known clashes with Semax.
Supports neuroregeneration and recovery from brain injury or stress-induced inflammation through angiogenic and anti-inflammatory tissue-repair pathways distinct from Semax's neurotrophic action. No interaction concerns; the two can run concurrently.
A copper peptide added for its anti-ageing and nerve-protecting effects alongside the thinking benefits.
Increases neurotrophic factor production and promotes nerve fibre regeneration, complementing BDNF-driven plasticity with matrix remodelling and antioxidant activity.
No known clash. Growth hormone peptides need to be taken on an empty stomach; Semax does not. Keep them on their own schedules.
No interaction concerns; entirely separate mechanisms. GH secretagogues require fasted administration whereas Semax does not, so the schedules are kept independent.
No known clash. Take Ipamorelin on an empty stomach as usual and Semax on its own morning schedule.
No interaction concerns. Distinct GHRH/ghrelin-axis mechanism; maintain separate fasted timing for the GH peptide.
No known clash. Different jobs entirely; keep each on its own timing.
No interaction concerns. Tesamorelin's GHRH-mediated action does not overlap with Semax's neurotrophic signalling; keep fasted GH dosing separate.
No known clash. These weight-loss peptides work on appetite and blood sugar, not on the brain pathways Semax uses. They can be run at the same time.
No interaction concerns; completely different incretin-based mechanisms. Concurrent use is acceptable.
- Testosterone replacement therapy
No known clash. Even though Semax comes from a hormone fragment, it does not touch hormone levels, so it can run alongside TRT.
No interaction concerns. Despite ACTH derivation, Semax lacks corticotropic activity and does not affect hormonal pathways; compatible with TRT.
- Caffeine
Coffee often feels stronger on Semax because Semax boosts what other things do to dopamine. That is expected, but go easy if you are sensitive to caffeine.
Semax potentiates dopamine release from other agents, so caffeine is frequently reported as more effective. This is the intended profile rather than an adverse effect; monitor for overstimulation in caffeine-sensitive individuals and avoid stacking with strong stimulants or MAO inhibitors.
Common questions
Does Semax affect cortisol?
No. Semax is made from only a small piece of the hormone ACTH (amino acids 4 through 10), the piece that helps brain cells rather than the piece that tells the adrenal glands to make cortisol. It has no effect on cortisol.
No. Semax uses only the ACTH (4-10) fragment responsible for neurotrophic effects and lacks the corticotropic sequence. It does not activate the adrenal cortex and does not alter cortisol production.
Is Semax a stimulant?
No. It does not directly push up dopamine or adrenaline. It makes your brain respond better to things that do, such as caffeine, and it raises BDNF, a growth protein for brain cells. Most people describe the feeling as sharper rather than wired.
No. Semax does not directly spike dopamine or noradrenaline. It potentiates dopamine release from other sources, increases serotonin turnover, and upregulates BDNF/TrkB. The subjective effect is optimisation rather than stimulation.
Can I take it by mouth?
No. Like other peptides it is broken down by stomach acid. It has to go by nasal spray or by injection under the skin.
No. Semax is degraded in gastric acid. Administration is intranasal or subcutaneous only.
Do I need to fast before injecting Semax?
No. Food does not change how it works. Just take it in the morning.
No fasting requirement; Semax does not interact with food absorption. Morning administration is the relevant timing constraint.
Can I use it long term?
Cycle it. The usual pattern is 10 to 14 days on, then 2 to 4 weeks off. Taking it every day without breaks gives smaller and smaller results because the brain adjusts.
Cycle it. Standard practice is 10 to 14 days on followed by 2 to 4 weeks off. Continuous stimulation of BDNF pathways produces adaptation and diminishing returns.
Does Semax cause hair loss?
Studies have not found hair loss as a side effect. Some users report temporary shedding, and the idea comes from a theory linking BDNF to hair growth cycles. If baldness runs in your family and you notice shedding, lower the dose or stop and see whether it settles.
Clinical studies have not documented hair loss. Some users report temporary shedding; the proposed BDNF–follicle cycling link is theoretical and unestablished. Those predisposed to androgenetic alopecia who notice shedding should reduce the dose or discontinue to test reversibility.
What is the difference between Semax and N-Acetyl Semax Amidate?
N-Acetyl Semax Amidate has small chemical caps on both ends of the chain that stop the body breaking it down as quickly. Users say it is stronger and longer lasting, so lower doses may be needed. There are no separate studies on it.
N-Acetyl Semax Amidate carries an N-terminal acetyl group and a C-terminal amide, conferring resistance to enzymatic degradation and potentially longer duration. Users report greater potency, so lower doses may be appropriate. The mechanism is the same; no separate clinical studies exist.
References
- Gusev EI, Martynov MY, Kostenko EV, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61-68.
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60.
- Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228.
- Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500.
- Ashmarin IP, Nezavibatko VN, Myasoedov NF, et al. A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Zh Vyssh Nerv Deiat Im I P Pavlova. 1997;47(2):420-430.
- Stavchansky VV, Yuzhakov VV, Botsina AY, et al. The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. J Mol Neurosci. 2011;45(2):177-185.
- Glazova NY, Merchieva SA, Sebentsova EA, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2009;29(6-7):871-878.
This entry has been reviewed and expanded with additional reference material. Units are recomputed from the stated protocol.